Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
HILLEMAN JERYL L reported acquisition or exercise transactions in this Form 4 filing.
SI-BONE, Inc. director Jeryl L. Hilleman received an equity grant in the form of 10,957 restricted stock units, each representing a contingent right to one share of common stock. The units were granted at $0.00 per share as director compensation, not an open-market purchase.
These restricted stock units will vest 100% on the earlier of the company’s next annual general meeting of stockholders or one year from the vesting commencement date, assuming continued board service. Following this award, Hilleman’s reported direct holdings total 43,772 shares of common stock, including the unvested units.
SI-BONE, Inc. director Jeffrey W. Dunn reported routine equity compensation and related tax sales. He received a grant of 10,957 shares of common stock as restricted stock units, which each represent a contingent right to one share and will vest in full at the earlier of the next annual stockholder meeting or one year from the vesting commencement date, subject to continued board service.
To cover tax withholding from RSU vesting, 3,575 shares of common stock were sold in open-market transactions at a weighted average price of $15.2462 per share in a non-discretionary “sell to cover” transaction. After these transactions, Dunn holds 16,057 shares directly and 81,073 shares indirectly through The Jeffrey W. Dunn Living Trust.
Nishimura Mika reported acquisition or exercise transactions in this Form 4 filing.
SI-BONE, Inc. director Mika Nishimura received a grant of 10,957 shares of common stock in the form of restricted stock units at no cash cost. Each unit represents a right to one share and will vest 100% at the next annual stockholder meeting or one year from the vesting start date, if she remains on the Board. Following this award, she directly holds 43,673 shares, including these unvested units.
West Thomas A. reported acquisition or exercise transactions in this Form 4 filing.
SI-BONE, Inc. director Thomas A. West reported receiving a grant of 10,957 shares of common stock in the form of restricted stock units at no cash cost. Following this award, he directly holds 37,947 shares, including 20,115 shares issuable upon settlement of previously granted restricted stock units.
The new restricted stock units will vest 100% on the earlier of the company’s next annual general meeting of stockholders or one year from the vesting commencement date, provided he continues to serve on the Board of Directors through that date.
SI-BONE, Inc. director John Gordon Freund reported a compensation-related equity grant rather than an open-market trade. He received 10,957 shares of Common Stock in the form of restricted stock units at $0.00 per share, classified as a grant or award acquisition. These restricted stock units will vest 100% on the earlier of the next annual general meeting of stockholders or one year from the vesting commencement date, subject to his continued board service. Following this award, he directly holds 54,258 shares, which include 10,957 shares issuable upon settlement of restricted stock units, and is also associated with 91,767 shares held indirectly through John Freund Family Partnership IV, L.P., for which he may be deemed to have voting and investment power but disclaims beneficial ownership except to the extent of his pecuniary interest.
Davis Timothy E JR reported acquisition or exercise transactions in this Form 4 filing.
SI-BONE, Inc. director Timothy E. Davis Jr. reported a grant of 10,957 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. These RSUs vest 100% at the earlier of the next annual general meeting or one year from the vesting commencement date, contingent on continued board service. Following this award, he is shown as directly holding 76,679 shares, including the RSUs.
SI-BONE, Inc. entered into a Third Amendment to its headquarters office lease with BIXBY SPE FINANCE 11, LLC, extending the lease term for 21,848 square feet at 471 El Camino Real in Santa Clara. The amendment provides for a one‑month extension from August 1, 2026 to August 31, 2026 with base rent of $43,696 per month, plus the company’s share of operating expenses and taxes, and includes an option for an additional one‑month extension to September 30, 2026 on the same terms.
The company also held its Annual Meeting of Stockholders, with 38,905,031 shares represented, about 88% of the 44,243,715 shares outstanding and entitled to vote as of the April 6, 2026 record date. Stockholders elected two directors to terms ending at the 2029 annual meeting, ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers.
SI-BONE, Inc. director Timothy E. Davis Jr. reported an option exercise and related share sales. On May 28, 2026, he exercised options for 12,064 shares of common stock at $4.32 per share, then sold 3,780 shares at a weighted average price of $14.4706. On May 29, 2026, he sold an additional 3,500 shares at a weighted average price of $14.1394. Following these transactions, he held 65,722 shares directly. A footnote states that this holding includes 8,675 shares issuable on settlement of restricted stock units.
SIBN filed a Form 144 reporting a proposed sale of 3,500 shares of Common Stock described as restricted stock. The filing also records a sale by Timothy E. Davis Jr. of 3,780 shares on 05/28/2026 for $54,698.87.
SI-BONE, Inc.’s Chief Executive Officer Laura Francis reported open-market sales of 14,957 shares of common stock on May 18, 2026, at weighted average prices around the mid-$14 range. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to vesting restricted stock units and were not discretionary trades.
Following the sales, Francis directly holds 540,476 shares of SI-BONE common stock. She also has indirect ownership of additional shares held by a family trust, providing substantial ongoing equity exposure despite the tax-related share sales.